The role of tuberous sclerosis complex 1 in regulating innate immunity

Journal of Immunology

Volumn 188, Issue 8, 2012, Pages 3658-3666

  Pan, Hongjie ^a   O'Brien, Thomas F ^a   Zhang, Ping ^a   Zhong, Xiao Ping ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; REGULATOR PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TOLL LIKE RECEPTOR; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NITRIC OXIDE; PHAGOCYTOSIS; PROTEIN KINASE INHIBITORS; PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84860333507     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102187     Document Type: Article

References (45)

1. Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
2. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145. (Pubitemid 33741967)
3. Barton, G. M., and J. C. Kagan. 2009. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9: 535-542.
4. Hoebe, K., X. Du, P. Georgel, E. Janssen, K. Tabeta, S. O. Kim, J. Goode, P. Lin, N. Mann, S. Mudd, et al. 2003. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748. (Pubitemid 37021696)
5. Ermolaeva, M. A., M. C. Michallet, N. Papadopoulou, O. Utermöhlen, K. Kranidioti, G. Kollias, J. Tschopp, and M. Pasparakis. 2008. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 9: 1037-1046.
6. Muzio, M., G. Natoli, S. Saccani, M. Levrero, and A. Mantovani. 1998. The human Toll signaling pathway: divergence of nuclear factor kappaB and JNK/ SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187: 2097-2101. (Pubitemid 28285580)
7. Muzio, M., J. Ni, P. Feng, and V. M. Dixit. 1997. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278: 1612-1615. (Pubitemid 27516277)
8. Pobezinskaya, Y. L., Y. S. Kim, S. Choksi, M. J. Morgan, T. Li, C. Liu, and Z. Liu. 2008. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 9: 1047-1054.
9. Wesche, H., W. J. Henzel, W. Shillinglaw, S. Li, and Z. Cao. 1997. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837-847. (Pubitemid 28064897)
10. Liew, F. Y., D. Xu, E. K. Brint, and L. A. O'Neill. 2005. Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458. (Pubitemid 40835033)
11. Sengupta, S., T. R. Peterson, and D. M. Sabatini. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 40: 310-322.
12. Powell, J. D., and G. M. Delgoffe. 2010. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33: 301-311.
13. Zhong, X. P., J. Shin, B. K. Gorentla, T. O'Brien, S. Srivatsan, L. Xu, Y. Chen, D. Xie, and H. Pan. 2011. Receptor signaling in immune cell development and function. Immunol. Res. 49: 109-123.
14. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189. (Pubitemid 34876546)
15. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
16. Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, and D. M. Sabatini. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11: 859-871. (Pubitemid 44804279)
17. Lee, K., P. Gudapati, S. Dragovic, C. Spencer, S. Joyce, N. Killeen, M. A. Magnuson, and M. Boothby. 2010. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32: 743-753.
18. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9: 324-337.
19. Gorentla, B. K., C. K. Wan, and X. P. Zhong. 2011. Negative regulation of mTOR activation by diacylglycerol kinases. Blood 117: 4022-4031.
20. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
21. Gulen, M. F., Z. Kang, K. Bulek, W. Youzhong, T. W. Kim, Y. Chen, C. Z. Altuntas, K. Sass Bak-Jensen, M. J. McGeachy, J. S. Do, et al. 2010. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32: 54-66.
22. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32: 67-78.
23. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844.
24. Weichhart, T., and M. D. Säemann. 2009. The multiple facets of mTOR in immunity. Trends Immunol. 30: 218-226.
25. Hackstein, H., T. Taner, A. F. Zahorchak, A. E. Morelli, A. J. Logar, A. Gessner, and A. W. Thomson. 2003. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101: 4457-4463. (Pubitemid 36857814)
26. + T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 115: 4758-4769.
27. Haidinger, M., M. Poglitsch, R. Geyeregger, S. Kasturi, M. Zeyda, G. J. Zlabinger, B. Pulendran, W. H. Hörl, M. D. Säemann, and T. Weichhart. 2010. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J. Immunol. 185: 3919-3931.
28. Weichhart, T., G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T. M. Stulnig, W. H. Hörl, M. Hengstschläger, et al. 2008. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577.
29. Zhao, J., M. R. Benakanakere, K. B. Hosur, J. C. Galicia, M. Martin, and D. F. Kinane. 2010. Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol. Immunol. 48: 294-304.
30. Schmitz, F., A. Heit, S. Dreher, K. Eisenächer, J. Mages, T. Haas, A. Krug, K. P. Janssen, C. V. Kirschning, and H. Wagner. 2008. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur. J. Immunol. 38: 2981-2992.
31. Ohtani, M., S. Nagai, S. Kondo, S. Mizuno, K. Nakamura, M. Tanabe, T. Takeuchi, S. Matsuda, and S. Koyasu. 2008. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharideinduced interleukin-12 production in dendritic cells. Blood 112: 635-643.
32. Cao, W. P., S. Manicassamy, H. Tang, S. P. Kasturi, A. Pirani, N. Murthy, and B. Pulendran. 2008. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTORp70S6K pathway. Nat. Immunol. 9: 1157-1164.
33. Colina, R., M. Costa-Mattioli, R. J. Dowling, M. Jaramillo, L. H. Tai, C. J. Breitbach, Y. Martineau, O. Larsson, L. Rong, Y. V. Svitkin, et al. 2008. Translational control of the innate immune response through IRF-7. Nature 452: 323-328. (Pubitemid 351430792)
34. Huang, J., and B. D. Manning. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412: 179-190. (Pubitemid 351758225)
35. Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17: 1829-1834. (Pubitemid 36944560)
36. Gan, B., E. Sahin, S. Jiang, A. Sanchez-Aguilera, K. L. Scott, L. Chin, D. A. Williams, D. J. Kwiatkowski, and R. A. DePinho. 2008. mTORC1dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc. Natl. Acad. Sci. USA 105: 19384-19389.
37. Chen, C., Y. Liu, R. Liu, T. Ikenoue, K. L. Guan, Y. Liu, and P. Zheng. 2008. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med. 205: 2397-2408.
38. Kwiatkowski, D. J., H. B. Zhang, J. L. Bandura, K. M. Heiberger, M. Glogauer, N. el-Hashemite, and H. Onda. 2002. A mouse model of TSC1 reveals sexdependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11: 525-534. (Pubitemid 34257489)
39. Shapiro-Shelef, M., K. I. Lin, D. Savitsky, J. Liao, and K. Calame. 2005. Blimp1 is required for maintenance of long-lived plasma cells in the bone marrow. J. Exp. Med. 202: 1471-1476. (Pubitemid 41746593)
40. Liu, C. H., F. S. Machado, R. Guo, K. E. Nichols, A. W. Burks, J. C. Aliberti, and X. P. Zhong. 2007. Diacylglycerol kinase zeta regulates microbial recognition and host resistance to Toxoplasma gondii. J. Exp. Med. 204: 781-792. (Pubitemid 46631608)
41. Chong-Kopera, H., K. Inoki, Y. Li, T. Zhu, F. R. Garcia-Gonzalo, J. L. Rosa, and K. L. Guan. 2006. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 281: 8313-8316. (Pubitemid 43847930)
42. Biswas, S. K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487.
43. Fukao, T., and S. Koyasu. 2003. PI3K and negative regulation of TLR signaling. Trends Immunol. 24: 358-363. (Pubitemid 36830961)
44. Luyendyk, J. P., G. A. Schabbauer, M. Tencati, T. Holscher, R. Pawlinski, and N. Mackman. 2008. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 180: 4218-4226.
45. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784. (Pubitemid 43090463)